Larson Financial Group LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 16.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,918 shares of the company’s stock after buying an additional 406 shares during the quarter. Larson Financial Group LLC’s holdings in Merck & Co., Inc. were worth $227,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cowen Prime Advisors LLC purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $31,000. AlphaMark Advisors LLC purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $39,000. Lake Point Wealth Management purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at approximately $40,000. ShoreHaven Wealth Partners LLC boosted its holdings in shares of Merck & Co., Inc. by 55.5% in the 1st quarter. ShoreHaven Wealth Partners LLC now owns 619 shares of the company’s stock worth $48,000 after purchasing an additional 221 shares during the period. Finally, Solstein Capital LLC purchased a new position in shares of Merck & Co., Inc. in the 1st quarter worth approximately $54,000. Institutional investors and hedge funds own 71.83% of the company’s stock.
Shares of NYSE MRK traded up $0.55 during trading hours on Wednesday, reaching $72.66. The stock had a trading volume of 245,894 shares, compared to its average volume of 11,229,302. Merck & Co., Inc. has a 52-week low of $71.71 and a 52-week high of $86.30. The firm has a market cap of $183.93 billion, a price-to-earnings ratio of 32.93, a P/E/G ratio of 2.16 and a beta of 0.41. The business’s fifty day moving average price is $76.68 and its two-hundred day moving average price is $76.59. The company has a current ratio of 1.31, a quick ratio of 1.06 and a debt-to-equity ratio of 0.72.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be issued a $0.65 dividend. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $2.60 annualized dividend and a dividend yield of 3.58%. Merck & Co., Inc.’s payout ratio is currently 43.77%.
A number of equities analysts have recently commented on the company. Zacks Investment Research upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price for the company in a report on Tuesday, August 24th. Argus reiterated a “hold” rating on shares of Merck & Co., Inc. in a report on Thursday, May 20th. SVB Leerink lifted their target price on Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Truist assumed coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They issued a “buy” rating and a $92.00 target price for the company. Finally, Truist Securities initiated coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They issued a “buy” rating and a $76.79 target price for the company. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $91.09.
Merck & Co., Inc. Company Profile
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.